Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages

  Mansell, Holly ^a   Rosaasen, Nicola ^b   Dean, Jonathan ^c   Shoker, Ahmed ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Health Region St Pauls Hospital   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cardiovascular risk; Chemokine; Framingham; Inflammation; Kidney transplant

Indexed keywords

BIOLOGICAL MARKER; CCL1 CHEMOKINE; CCL15; CUTANEOUS T CELL ATTRACTING CHEMOKINE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FRAMINGHAM RISK SCORE; GRAFT RECIPIENT; HUMAN; INFLAMMATION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PARAMETERS; PRIORITY JOURNAL;

CARDIOVASCULAR RISK; CHEMOKINE; FRAMINGHAM; INFLAMMATION; KIDNEY TRANSPLANT;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS;

EID: 84881549985     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12159     Document Type: Article

References (43)

1. Collins AJ, Foley RN, Herzog C et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011: 57(Suppl. 1): A8. e1-526.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004: 4: 1289.
3. Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendation. Can J Cardiol 2009: 25: 567.
4. D'Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008: 117: 743.
5. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease after renal transplantation. J Am Soc Nephrol 2000: 11: 1735.
6. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004: 66: 441.
7. Silver SA, Huang M, Nash MM, Prasad GV. Framingham risk score and novel cardiovascular risk factors underpredict major cardiac events in kidney transplant recipients. Transplantation 2011: 92: 183.
8. Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham score revisited. Clin J Am Soc Nephrol 2008: 3: 822.
9. Dahle DO, Mjøen G, Oqvist B et al. Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant 2011: 26: 3756.
10. Abedini S, Holme I, März W et al. on behalf of the ALERT study group. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009: 4: 1246.
11. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
12. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010: 86: 192.
13. Chung ACK, Lan HY. Chemokines in renal injury. J Am Soc Nephrol 2011: 22: 802.
14. Baay-Guzman GJ, Bebenek IG, Zeidler M et al. HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation. Respir Res 2012: 13: 60.
15. Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 2013: 36: 364.
16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005: 352: 1685.
17. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damås JK. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007: 97: 748.
18. Montecucco F, Mach F, Pende A, Schindler TH, Da Silva RF, Vuilleumier N. Inflammatory cardiovascular risk biomarkers: update on novelties and limitations. Mediators Inflamm 2012: 107: 124.
19. Eis V, Vielhauer V, Anders HJ. Targeting the chemokine network in renal inflammation. Arch Immunol Ther Exp (Warsz) 2004: 52: 164: Review.
20. Hribova P, Kotsch K, Brabcova I, Vitko S, Volk HD, Lacha J. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005: 37: 760.
21. Mayer V, Hudkins KL, Heller F et al. Expression of the chemokine receptor CCR1 in human renal allografts. Nephrol Dial Transplant 2007: 22: 1720.
22. Hribova P, Lacha J, Kotsch K et al. Cytokine and chemokine gene expression and kidney graft outcome. Kidney Blood Press Res 2007: 30: 273.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010: 33(Suppl. 1): S62.
24. Kumar AR, Li X, Leblanc JF et al. Proteomic analysis reveals innate immune activity in intestinal transplant dysfunction. Transplantation 2011: 92: 112.
25. De Pádua Netto MV, Bonfim TC, Costa EN, De Lima HV, Netto LC. Cardiovascular risk estimated in renal transplant recipients with the Framingham Score. Transplant Proc 2012: 44: 2337.
26. Bosomworth JN. Practical use of the Framingham risk score in primary prevention. Can Fam Physician 2011: 57: 417.
27. Leite D, Campos AH. A Strategy to improve the cardiovascular risk profile in renal transplant patients. Arq Bras Cardiol 2010: 94: 738.
28. Israni AK, Snyder JJ, Skeans MA et al. PORT Investigators. Predicting coronary heart disease after kidney transplantation: patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010: 10: 338.
29. Matsushita K, Van Der Velde M, Astor BC et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010: 375: 2073.
30. Meier-Kriesche HU, Bailga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003: 75: 1291.
31. Soveri I, Holdaas H, Jardine A et al. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006: 21: 2282.
32. Abbott KC, Bucci JR, Cruess BD, Taylor AJ, Agodas LYC. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002: 13: 2560.
33. Phelan PJ, O'Kelly P, Tarazi M et al. Renal allograft loss in the first post-operative month: causes and consequences. Clin Transplant 2012: 26: 544.
34. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000: 57: 307.
35. Banas MC, Banas B, Orth SR et al. Traditional and nontraditional cardiovascular risk factors and estimated risk for coronary artery disease in renal transplant recipients: a single-center experience. Nephron Clin Pract 2011: 119: c227.
36. Belperio JA, Ardehali A. Chemokines and transplant vasculopathy. Circ Res 2008: 103: 454.
37. Pereira AB, Teixeira AL, Rezende NA et al. Urinary chemokines and anti-inflammatory molecules in renal transplanted patients as potential biomarkers of graft function: a prospective study. Int Urol Nephrol 2012: 44: 1539.
38. Rotondi M, Rosati A, Buonamano A et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004: 4: 1466.
39. Lazzeri E, Rotondi M, Mazzinghi B et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005: 9: 1215.
40. Hwang J, Kim CW, Son KN et al. Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett 2004: 570: 47.
41. Lee WH, Kim SH, Jeong EM et al. A novel chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor expression in atherosclerosis. Atherosclerosis 2002: 161: 255.
42. Richter R, Forssmann U, Henschler R, Escher S, Frimpong-Boateng A, Forssmann WG. Increase of expression and activation of chemokine CCL15 in chronic renal failure. Biochem Biophys Res Commun 2006: 345: 1504.
43. Starr AE, Dufour A, Maier J, Overall CM. Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16. J Biol Chem 2012: 287: 5848.